Clinical trials: Metabolic Dysfunction-associated Steatotic Liver Disease
Metabolic Associated-dysfunction Steatotic Liver Disease (MASLD), Metabolic Associated-dysfunction Steatohepatitis (MASH)
Behavioral Lifestyle Intervention for Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) in Adults
The goal of this randomized control trial study is to compare an acceptance-based weight loss program with an occupational therapy behavioral lifestyle modification intervention in adults with metabolic associated-dysfunction…
- Trial name
- NCT06121999
- Testing
- Standard of care acceptance-based behavioral weight loss program, Occupational therapy dietary and lifestyle modifications
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Grand Valley State University
Metabolic Dysfunction-Associated Steatotic Liver Disease
Development of Microbial Therapeutics for Metabolic-associated Fatty Liver Disease: From Mechanistic Investigations to Clinical Trials
The goal of this clinical trial is to investigate the efficacy and safety of pasteurized Akkermansia muciniphila strain NTUH_Amuc03 (pAKK NTUH_Amuc03) in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)Patients.
- Trial name
- NCT06873165
- Testing
- Probiotics
- Where
- Taiwan
- Volunteers
- 40 people
- Sponsor
- National Taiwan University Hospital
MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Cirrhosis
Screening Cardiometabolic Opportunities Using Transformative Echocardiography Artificial Intelligence (SCOUT Echo-AI)
The goal of this prospective, multicenter, open-label, blinded end-point pragmatic study is to evaluate an artificial intelligence (AI)-augmented echocardiography screening approach for early detection of metabolic dysfunction…
- Trial name
- SCOUT Echo-AI (NCT07216859)
- Testing
- AI-Enabled Identification (EchoNet-Liver)
- Where
- 6 sites in United States
- Volunteers
- 2,000 people
- Sponsor
- Kaiser Permanente
Type 2 Diabetes Mellitus (T2DM), Metabolic Dysfunction-Associated Steatotic Liver Disease
Accelerated Biological Aging is Associated With Increased Risk of T2DM in the MASLD Population
The association between biological aging and type 2 diabetes mellitus (T2DM) incidence in individuals with and without metabolic dysfunction-associated steatotic liver disease (MASLD) remains unclear.We assessed biological age by…
- Conditions
- Type 2 Diabetes Mellitus (T2DM), Metabolic Dysfunction-Associated Steatotic Liver Disease, Biological Age
- Trial name
- NCT06984510
- Testing
- Observational
- Where
- China
- Volunteers
- 2,720 people
- Sponsor
- Ningbo No. 1 Hospital
Obstructive Sleep Apnea
Vitamin D and SGLT-2 Inhibitor in CPAP-naive Obstructive Sleep Apnea
The purpose of this study is to determine if vitamin D supplement and SGLT-2 inhibitor treatment combination can improve cardiovascular risks in patients with OSA and hypertension, on top of lifestyle modification, before…
- Trial name
- D3DOSA (NCT06690723)
- Testing
- Dapagliflozin (Forxiga), Vitamin D3 ( Colecalciferol), Vitamin D3 plus Dapagliflozin
- Where
- Malaysia
- Volunteers
- 160 people
- Sponsor
- University Malaysia Sarawak
Metabolic Dysfunction-Associated Steatotic Liver Disease
Efficacy and Safety of Rifaximin-α in Treating MASLD
Study Objective: To evaluate the efficacy and safety of Rifaximin-α in the treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), and investigate the underlying mechanisms by which Rifaximin-α influences…
- Trial name
- NCT07381257
- Testing
- Rifaximin-α (Alfa Wassermann S.p.A., Italy)
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shanghai Changzheng Hospital
Metabolic Dysfunction-Associated Steatotic Liver Disease
Using Digital Twin Technology and Clinical Decision Support Systems to Improve the Early Detection, Personalised Treatment, and Long-term Monitoring of Patients Across the Full Spectrum of Metabolic-associated Fatty Liver Disease (MAFLD).
The goal of this observational study is to create a detailed virtual model to better understand how Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) develops.
- Trial name
- ARTEMIS (NCT07430501)
- Testing
- Data recollection
- Where
- Spain
- Volunteers
- 7,720 people, healthy volunteers welcome
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
MASLD, Fibrosis of Liver
Improving Liver Fibrosis Diagnosis in Primary Care Using FibroX AI
The goal of this clinical trial is to learn whether an artificial intelligence (AI) tool called FibroX can help primary care providers better diagnose significant liver fibrosis (≥F2) and clinically significant portal…
- Trial name
- NCT07305324
- Testing
- FibroX, Usual Care
- Volunteers
- 40 people
- Sponsor
- Yale University
MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Obesity
Effect of Ketone Esters on Liver Fat Content and Metabolic Function
The goal of this clinical trial is to determine whether ingestion of a ketone ester drink helps improve liver health and blood glucose control.
- Conditions
- MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Obesity, Overweight (BMI > 25)
- Trial name
- JV (NCT07097506)
- Testing
- bis-octanoyl (R)-1,3-butanediol (C8 ketone di-ester)
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Sarcopenia Among Patients With Metabolic Dysfunction-associated Steatotic Liver Disease
Sarcopenia Among Patients With Metabolic Dysfunction-associated Steatotic Liver Disease
Determination of sarcopenia frequency among patients with metabolic dysfunction-associated steatotic liver disease 2- Exploring the association of sarcopenia with disease state (steatosis grade and fibrosis) among patients with…
- Trial name
- NCT07598916
- Volunteers
- 120 people
- Sponsor
- Assiut University
Metabolic Dysfunction-associated Steatotic Liver Disease
Advanced Fibrosis Detection for MASLD in Primary Care
This proposal evaluates the implementation of a novel, non-interruptive, electronic health record alert for metabolic dysfunction-associated steatotic liver disease (MASLD) fibrosis risk assessment in primary care patients with…
- Trial name
- NCT07159386
- Testing
- EHR alert
- Where
- United States
- Volunteers
- 225 people
- Sponsor
- Medical University of South Carolina
CVD - Cardiovascular Disease, MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
Corazones Unidos Study
CVD is the leading cause of death among individuals with MASLD, a risk factor for liver cancer. In Southern Arizona, CVD and cancer (including liver and gastric cancer) are among the leading causes of death for Mexican-origin…
- Trial name
- NCT07298213
- Testing
- Your Heart, Your Health
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- University of Arizona
MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Assessment of Gut Microbiota-Derived Amino Acid Metabolite Production in Patients With MASLD
Metabolic dysfunction-associated steatotic liver disease (MASLD) encompasses a spectrum of liver disorders ranging from simple steatosis-a relatively benign and non-progressive condition-to metabolic dysfunction-associated…
- Trial name
- MASLD-GUT (NCT07313007)
- Testing
- stool sampling, dietary assessment, and collection of blood and urine samples
- Where
- France
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Hospices Civils de Lyon
MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, HIV (Human Immunodeficiency Virus)
A Study to Evaluate the Use of Resmetirom in Participants With MASLD and HIV
The purpose of this research study is to test the safety and effectiveness of the study drug, resmetirom, in participants with MASLD and HIV.
- Trial name
- NCT07143968
- Testing
- Resmetirom
- Where
- 10 sites in United States
- Volunteers
- 120 people
- Sponsor
- Naga P. Chalasani
Diabetes Mellitus, Type 2, Liver Fibrosis
Effect of an Early Time Restricted Eating Mediterranean Diet Compared to Naltrexone/Bupropion on Liver Fibrosis in People With Cardiometabolic Risk Factors in a Hospital Outpatient Clinic (MEDFAST-study)
In the Netherlands, there are many people with cardiometabolic diseases. More than half of these people also have fatty liver. This is a build-up of fat in the liver (steatosis) and can lead to long-term scarring (fibrosis) and…
- Conditions
- Diabetes Mellitus, Type 2, Liver Fibrosis, Liver Steatoses, Hepatic Steatosis
- Trial name
- MEDFAST (NCT06845345)
- Testing
- early time restricted Mediterranean diet, Mysimba
- Where
- Netherlands
- Volunteers
- 70 people
- Sponsor
- Carmen Dietvorst
MASLD, Pediatric
Ultrasound-Based Estimation of Hepatic Steatosis in Pediatric MASLD
The purpose of this study is to validate an artificial intelligence (AI)-based algorithm that estimates hepatic steatosis using ultrasound (US) B-mode images in pediatric participants with metabolic dysfunction-associated…
- Trial name
- NCT07265011
- Testing
- Ultrasound and MRI
- Where
- South Korea
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Jae Won Choi
MASLD, Chronic Kidney Diseases
Safety and Efficacy of Finerenone in Metabolic Dysfunction Associated Steatotic Liver Disease(MASLD/NAFLD) Related Cirrhosis Patients With Ascites in Prevention of Chronic Kidney Disease.
Renal dysfunction is a frequent and clinically important complication in cirrhosis, and MASLD/NAFLD is associated with increased risk of incident CKD; however, finerenone has not been specifically studied in MASLD-cirrhosis…
- Trial name
- NCT07585526
- Testing
- Finerenone, Spironolactone, Standard Medical Treatment
- Where
- India
- Volunteers
- 160 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Nonalcoholic Fatty Liver Disease, Nonalcoholic Fatty Liver Disease (NAFLD)
The Impact of Pectin Supplementation on Systematic Inflammation Pathway, Gut Microbiome, and Metabolic Health in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
The goal of this clinical trial is to learn if daily supplementation with Low-methoxy (LM) pectin (polysaccharides extracted from citrus peels), which are commonly found in the UK diet (not pharmacological agents), can reduce…
- Conditions
- Nonalcoholic Fatty Liver Disease, Nonalcoholic Fatty Liver Disease (NAFLD), MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD
- Trial name
- PEC-MASLD (NCT07093346)
- Testing
- Pectin, Cocoa Powder, Magnetic Resonance Imaging with Contrast
- Where
- 3 sites in United Kingdom
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- University of Nottingham
Metabolic Dysfunction-Associated Steatotic Liver Disease, Non-Alcoholic Fatty Liver Disease
Impact of Overt and Subclinical Hypothyroidism on Liver Fibrosis in Patients With MASLD
Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease (NAFLD), is one of the most common chronic liver conditions globally.
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease, Non-Alcoholic Fatty Liver Disease, Hypothyroidism, Liver Fibrosis
- Trial name
- NCT07827430
- Volunteers
- 120 people
- Sponsor
- Assiut University
MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Food Insecurity Among Children
Food Insecurity and MASLD: A Fruit and Vegetable Intervention Study
This proposal addresses a critical gap in the understanding of the impact of household food insecurity (FI) on pediatric metabolic dysfunction-associated steatotic liver disease (MASLD) severity.
- Trial name
- NCT07091539
- Testing
- Fruit/vegetable vouchers
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- University of California, San Francisco